Mobia Medical (NASDAQ:MOBI – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.27), FiscalAI reports. The firm had revenue of $13.51 million during the quarter. The company’s quarterly revenue was up 102.4% on a year-over-year basis.
Here are the key takeaways from Mobia Medical’s conference call:
- Q2 revenue doubled year over year to $13.5 million, supported by broader Vivistim adoption, while gross margin increased to 83.2%. Management initiated 2026 revenue guidance of $54 million to $56 million, implying 69% to 75% growth.
- Commercial expansion continued, with average active territories rising 92% year over year to 35.5 and approximately 367 Vivistim units sold in the quarter. Management expects to add roughly four to five active territories in the second half while maintaining a measured expansion strategy.
- The May IPO generated approximately $134 million in net proceeds, leaving $177.1 million in cash and equivalents at quarter-end. The company plans to invest primarily in sales hiring, geographic expansion, patient awareness, and clinical evidence.
- CMS assigned Vivistim’s Category 1 CPT code to New Technology APC 1580 for 2026, representing Medicare reimbursement of approximately $45,000; however, the proposed 2027 payment classification is not final until November. Commercial payer coverage remains a multiyear development effort, though some insurers are already paying claims.
- Operating expenses grew faster than revenue, with SG&A up 85% to $26.9 million and R&D up 61% to $2.3 million. Net loss increased to $21.0 million, including a one-time, non-cash $4 million charge related to the conversion of convertible notes.
Mobia Medical Stock Down 1.2%
MOBI traded down $0.15 during midday trading on Tuesday, hitting $12.58. 97,297 shares of the company traded hands, compared to its average volume of 147,037. The firm has a 50-day moving average of $12.54. The firm has a market cap of $418.29 million and a price-to-earnings ratio of -0.65. Mobia Medical has a 52 week low of $10.19 and a 52 week high of $15.29.
Insider Activity at Mobia Medical
Analyst Upgrades and Downgrades
MOBI has been the subject of a number of analyst reports. Zacks Research upgraded shares of Mobia Medical to a “hold” rating in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. initiated coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They set an “overweight” rating and a $15.00 price target on the stock. Wolfe Research initiated coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They set an “outperform” rating for the company. BTIG Research initiated coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $19.00 price objective for the company. Finally, Wall Street Zen raised Mobia Medical from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.25.
Check Out Our Latest Stock Analysis on Mobia Medical
Mobia Medical Company Profile
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.
Read More
- Five stocks we like better than Mobia Medical
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Mobia Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mobia Medical and related companies with MarketBeat.com's FREE daily email newsletter.
